The Central Protocol and Data Monitoring Office (CPDMO) is a Shared Resource that provides a number of centralized clinical research protocol-related services. The primary objectives of the CPDMO Shared Resource are to support Cancer Center clinical investigators by providing assistance in developing high quality clinical protocols, ensuring that all appropriate institutional and Federal reviews have been accomplished prior to accruing participants, providing standard order sets for therapeutic protocols, ensuring appropriate research participant enrollment via a centralized clinical trial registration system, coordinating efforts to design and develop case report forms, ensuring appropriate scientific review, and monitoring of clinical research studies. The CPDMO is a key component of the Clinical Trials Infrastructure. It was proposed by the Clinical Academic Council and approved by the Director in 1995, replacing the Protocol Office which previously managed clinical research protocols. The CPDMO has grown from 5.5 FTEs to 26 FTEs (including the Investigational Studies Pharmacists) to meet the demands of an every-changing regulatory environment and to meet the institutional commitment to human subjects'protection and data integrity. A centralized research participant enrollment system was fully implemented in 1998, along with monitoring of protocol eligibility for 100% of participants who are enrolled on St. Jude protocols. In 1999, an automated clinical trials database application was installed. A program to monitor our institutional trials for protocol compliance, regulatory compliance and data quality was established in the fall of 2000. Therapeutic and non-therapeutic studies are monitored in accordance with the current Data and Safety Monitoring Plan (dated 2001). The office is heavily involved with the assurance of appropriate institutional, legal, scientific, and regulatory review of all clinical research protocols conducted at St. Jude. A recent review of processes showed that St. Jude's clinical research infrastructure is superior to that of benchmarked institutions, and provides researchers with unique opportunities that are unavailable elsewhere. The effort placed in monitoring and organization has had significant positive impact on the quality of research conducted at St. Jude. As the number of clinical trials with external collaborating sites increases, resources to support those sites have also been added, including monitors/auditors who review study information on site. Upgrades to the clinical trials database and enrollment system are ongoing to meet current and future needs. To meet the future needs of clinical research, the institutional clinical trials infrastructure will continue to evolve. The Institutional Data and Safety Monitoring Plan is being revised to incorporate a more risk-based approach to monitoring and auditing. The monitoring program will be moved into Cancer Center Operations in order to allow for real time monitoring of key aspects of the research. A separate institutional auditing function will review clinical research studies at regular intervals. Restructuring of CPDMO functions in the context of the Cancer Center and Institution will allow us to capitalize on strengths and to be good stewards of institutional resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA021765-34W1
Application #
8738011
Study Section
Special Emphasis Panel (ZCA1-RTRB-Z)
Project Start
2012-03-01
Project End
2014-02-28
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
34
Fiscal Year
2013
Total Cost
$802
Indirect Cost
$344
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Hatfield, M Jason; Binder, Randall J; Gannon, Rowan et al. (2018) Potent, Irreversible Inhibition of Human Carboxylesterases by Tanshinone Anhydrides Isolated from Salvia miltiorrhiza (""Danshen""). J Nat Prod 81:2410-2418
Vo, BaoHan T; Kwon, Jin Ah; Li, Chunliang et al. (2018) Mouse medulloblastoma driven by CRISPR activation of cellular Myc. Sci Rep 8:8733
Shadrick, William R; Slavish, Peter J; Chai, Sergio C et al. (2018) Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors. Bioorg Med Chem 26:25-36
Ramsey, Laura B; Balis, Frank M; O'Brien, Maureen M et al. (2018) Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance. Oncologist 23:52-61
Churchman, Michelle L; Qian, Maoxiang; Te Kronnie, Geertruy et al. (2018) Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. Cancer Cell 33:937-948.e8
Huang, I-Chan; Brinkman, Tara M; Mullins, Larry et al. (2018) Child symptoms, parent behaviors, and family strain in long-term survivors of childhood acute lymphoblastic leukemia. Psychooncology 27:2031-2038
Huang, I-Chan; Klosky, James L; Young, Chelsea M et al. (2018) Misclassification of self-reported smoking in adult survivors of childhood cancer. Pediatr Blood Cancer 65:e27240
Mandrell, Belinda N; Avent, Yvonne; Walker, Breya et al. (2018) In-home salivary melatonin collection: Methodology for children and adolescents. Dev Psychobiol 60:118-122
Drummond, Catherine J; Hanna, Jason A; Garcia, Matthew R et al. (2018) Hedgehog Pathway Drives Fusion-Negative Rhabdomyosarcoma Initiated From Non-myogenic Endothelial Progenitors. Cancer Cell 33:108-124.e5
Jones, Conor M; Baker, Justin N; Keesey, Rachel M et al. (2018) Importance ratings on patient-reported outcome items for survivorship care: comparison between pediatric cancer survivors, parents, and clinicians. Qual Life Res 27:1877-1884

Showing the most recent 10 out of 6764 publications